within Pharmacolibrary.Drugs.ATC.C;

model C09AA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.001999999999999
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09AA15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor used for treatment of hypertension and heart failure. It is a prodrug hydrolyzed to its active form, zofenoprilat. Zofenopril has been approved for clinical use in several countries, primarily in Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Marzo, A, et al., &amp; Giusti, A (1999). Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. <i>Arzneimittel-Forschung</i> 49(12) 992–996. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1300539&quot;>10.1055/s-0031-1300539</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10635443/&quot;>https://pubmed.ncbi.nlm.nih.gov/10635443</a></p></li><li><p>DeForrest, JM, et al., &amp; Petrillo, EW (1989). Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. <i>Journal of cardiovascular pharmacology</i> 13(6) 887–894. DOI:<a href=&quot;https://doi.org/10.1097/00005344-198906000-00011&quot;>10.1097/00005344-198906000-00011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2484083/&quot;>https://pubmed.ncbi.nlm.nih.gov/2484083</a></p></li><li><p>Chen, BL, et al., &amp; Zhang, W (2015). Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. <i>Therapeutics and clinical risk management</i> 11 309–318. DOI:<a href=&quot;https://doi.org/10.2147/TCRM.S64288&quot;>10.2147/TCRM.S64288</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25750535/&quot;>https://pubmed.ncbi.nlm.nih.gov/25750535</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09AA15;
